202 related articles for article (PubMed ID: 37159987)
1. L-Asparaginase delivery systems targeted to minimize its side-effects.
Talluri VP; Mutaliyeva B; Sharipova A; Ulaganathan V; Lanka SS; Aidarova S; Suigenbayeva A; Tleuova A
Adv Colloid Interface Sci; 2023 Jun; 316():102915. PubMed ID: 37159987
[TBL] [Abstract][Full Text] [Related]
2. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
4.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
5. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase.
Hermanova I; Zaliova M; Trka J; Starkova J
Exp Hematol; 2012 Aug; 40(8):657-65. PubMed ID: 22542578
[TBL] [Abstract][Full Text] [Related]
6. A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia.
Freire DA; Lisboa Magalháes IC; Tramontina Florean EOP; Florindo Guedes MI
Recent Adv Drug Deliv Formul; 2021; 15(1):37-45. PubMed ID: 33685385
[TBL] [Abstract][Full Text] [Related]
7. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
Sindhu R; Manonmani HK
Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
[TBL] [Abstract][Full Text] [Related]
8. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; Stigter RL; van Wering ER; Janka-Schaub GE; Slater R; Pieters R
Blood; 2003 Apr; 101(7):2743-7. PubMed ID: 12433682
[TBL] [Abstract][Full Text] [Related]
10. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
[TBL] [Abstract][Full Text] [Related]
11. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
[TBL] [Abstract][Full Text] [Related]
12. PEG-asparaginase.
Fu CH; Sakamoto KM
Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
[TBL] [Abstract][Full Text] [Related]
13. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
15. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Qiao J; Qi L; Mu X; Chen Y
Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
[TBL] [Abstract][Full Text] [Related]
16. [Update on L-asparaginase treatment in paediatrics].
Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
[TBL] [Abstract][Full Text] [Related]
18. An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.
Gutierrez JA; Pan YX; Koroniak L; Hiratake J; Kilberg MS; Richards NG
Chem Biol; 2006 Dec; 13(12):1339-47. PubMed ID: 17185229
[TBL] [Abstract][Full Text] [Related]
19. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
20. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
